Abiomed CFO Bowen to retire

 Robert Bowen,  Abiomed’s vice president and chief financial officer since 2008, announced he will be retiring on July 15. Bowen will be celebrating his 66th birthday this summer.

Michael Tomsicek will be appointed as vice president and chief financial officer of the Danvers-based medical device company, effective July 15.

 Bowen will continue to support the company in a consulting role to facilitate a smooth transition.

“The opportunity to serve as the vice president and chief financial officer of Abiomed has been the most professionally rewarding experience of my 43 year career. For me, I could not envision a better ending. I cannot thank Mike Minogue enough for providing me with the opportunity and the Abiomed team for providing the support necessary to be successful in this role,” said Bowen. “Abiomed will have a tremendous future and I have much personal and professional satisfaction and pride from playing a small part in building the foundation.”

“Bob has served as our CFO for the past seven years as Abiomed has grown revenue greater than three times, market capitalization four times and become GAAP profitable with no debt,” said Michael R. Minogue, chairman, president and chief executive officer of Abiomed. “His leadership, expertise and consistent excellence in fiscal compliance have been instrumental to Abiomed’s success and we are appreciative of his contributions to the company and commitment to patient care.”

“We are pleased to welcome Mike Tomsicek to the executive team during this exciting time as Abiomed experiences tremendous growth with the Impella platform. Mike has over 20 years of experience in senior management roles in finance, operations and globalization. We look forward to working with him as Abiomed continues to grow and become the standard of care,” said  Minogue.

 Tomsicek, 49, joins Abiomed after he most recently served as CFO of Lexington-based Cubist Pharmaceuticals. He joined Cubist in 2010 and held a series of roles of increasing responsibility leading finance, investor relations and strategic sourcing through a very dynamic period at the company.

Cubist, a global bio-pharmaceutical company, was recently acquired in January 2015 for $9.5 billion by Merck & Co Inc.

Prior to Cubist, Tomsicek spent nearly eight years at General Electric Healthcare, initially as finance manager of its global operations, and then as CFO of two of its largest businesses.

Previously, Tomsicek served in a variety of financial and operational roles at Motorola. He holds a bachelor of science degree in engineering and a master of business administration, both from the University of Wisconsin.

“Abiomed has built a revolutionary platform of minimally invasive heart pumps and a world-class business organization. I am excited to step into this role and work closely with Abiomed’s employees and shareholders,” said Tomsicek. “Abiomed is an innovative leader in its space and I look forward to furthering the company’s tradition of commitment to patients, fiscal discipline and growing shareholdervalue.”